Table 1. Characteristics of included studies.
| Studies | Country | Study design | No. of patients | Type II endoleaks | types of endoleaks | Reintervention | Follow-up (months) | Surveillance test |
|---|---|---|---|---|---|---|---|---|
| Chuter 2001[16] | USA | retrospective | 114 | 9 | Any | n.s. | n.s. | CTA |
| Haulon 2001[17] | France | retrospective | 60 | 18 | Any | n.s. | 13.3 | CTA/MRI |
| Liewald 2001[18] | Germany | retrospective | 160 | 13 | Any | n.s. | n.s. | CTA |
| Buth 2002[19]* | Netherland | retrospective | 3529 | 240 | Any | 53 | n.s. | CTA |
| Parent 2002[20] | USA | retrospective | 83 | 36 | Any | 3 | 20.7 | CTA |
| Solis 2002[21] | USA | retrospective | 119 | 14 | Any | 10 | 18.2 | CTA |
| Tuerff 2002[22] | USA | prospective | 130 | 22 | Any | n.s. | 15.7 | CTA |
| Faries 2003[23] | USA | retrospective | 597 | 16 | Any | n.s. | 24.5 | CTA |
| Farner 2003[24] | USA | retrospective | 63 | 9 | Any | n.s. | 12 | CTA |
| Kasirajan 2003[25] | USA | retrospective | 104 | 8 | Any | n.s. | n.s. | CTA |
| Carpenter 2004[26] | USA | prospective | 227 | 21 | Any | 8 | n.s. | CTA |
| Steinmetz 2004[27] | USA | retrospective | 486 | 90 | Any | 4 | 21.7 | CTA |
| Van Marrewijk 2004[28]* | Netherland | prospective | 3595 | 320 | Any | n.s. | 15 | CTA |
| Tolia 2005[29] | USA | retrospective | 83 | 16 | Any | 2 | 30 | CTA |
| Sheehan 2006[30] | USA | retrospective | 1909 | 221 | Any | 101 | 36 | CTA |
| Silverberg 2006[31] | USA | retrospective | 965 | 154 | Any | 19 | 22 | CTA |
| Jones 2007[8] | USA | retrospective | 873 | 164 | Any | 16 | 38 | CTA |
| Abularrage 2010[9] | USA | retrospective | 832 | 136 | Persistent | 39 | 34.8 | CTA |
| Brountzos 2012[10] | Greece | retrospective | 136 | 31 | Persistent | n.s. | 13.5 | CTA |
| Koole 2012[32]* | Netherland | prospective | 8638 | 4518 | Any | 661 | 26 | CTA |
| Nolz 2012[33] | Austria | retrospective | 407 | 49 | Any | 20 | n.s. | CTA |
| Batti 2013[34] | France | prospective | 700 | 201 | Any | 30 | 31.3 | CTA |
| Chang 2013[35] | USA | retrospective | 1736 | 474 | Any | 251 | 32.4 | CTA |
| Jouhannet 2013[36] | France | retrospective | 232 | 94 | Any | 14 | 23 | CTA |
| Cieri 2014[37] | Italy | prospective | 1412 | 218 | Any | 52 | 45 | CTA |
| Maeda 2014[11] | Japan | retrospective | 469 | 111 | Any | n.s. | 21.0 | CTA |
| Sidloff 2014[38] | UK | prospective | 904 | 175 | Any | 9 | 43.2 | DUS |
| Ward 2014[39] | USA | retrospective | 326 | 99 | Any | n.s. | n.s. | CTA |
| Dudeck 2015[40] | Germany | retrospective | 188 | 62 | Any | n.s. | 39 | CTA |
| Hiraoka 2015[41] | Japan | retrospective | 148 | 36 | Any | n.s. | 28.8 | CTA |
| Löwenthal 2015[42] | Germany | retrospective | 130 | 62 | Any | n.s. | 22 | CTA |
| Müller-Wille 2015[43] | Germany | retrospective | 384 | 56 | Any | 20 | 36 | CTA |
| Gallitto 2015[44] | Italy | prospective | 200 | 47 | Any | 6 | 22 | CTA |
| Kray 2015[45] | USA | retrospective | 191 | 18 | Any | n.s. | n.s. | CTA |
| Nolz 2015[46] | Austria | retrospective | 143 | 69 | Any | n.s. | n.s. | CTA |
| Pini 2015[47] | Italy | retrospective | 753 | 85 | Any | 2 | 19 | CTA/DUS |
| Walker 2015[48] | USA | retrospective | 1736 | 474 | Any | 111 | 32.2 | CTA |
| Rousié 2015[49] | Belgium | retrospective | 77 | 17 | Any | 0 | 79 | CTA |
| Phan 2015[50] | Germany | retrospective | 82 | 51 | Any | 13 | 29.5 | CTA |
| Piazza 2016[51] | USA | prospective | 126 | 34 | Any | 7 | 16 | CTA |
| Lo 2016[52] | USA | retrospective | 2367 | 807 | Persisent | n.s. | 15.4 | n.s. |
| Mursalin 2016[53] | Japan | retrospective | 145 | 47 | Any | n.s. | n.s. | CTA |
| Ikoma 2016[54] | Japan | prospective | 34 | 12 | Any | n.s. | n.s. | CTA |
| Pippin 2016[55] | USA | retrospective | 163 | 66 | Any | 4 | 24.7 | CTA |
| Fujimura 2016[56] | Japan | retrospective | 832 | 234 | Any | 11 | 35.6 | CTA/MRI |
*Three papers were published from the EUROSTAR registry and may present duplicated data.
n.s., Not stated.